Literature DB >> 10768952

Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal.

C Oeuvray1, M Theisen, C Rogier, J F Trape, S Jepsen, P Druilhe.   

Abstract

The goal of this study was to analyze antibody responses to Plasmodium falciparum glutamate-rich protein (GLURP) using clinical data and plasma samples obtained from villagers of Dielmo, Senegal. This molecule was chosen because it is targeted by human antibodies which induce parasite growth inhibition in antibody-dependent cellular inhibition (ADCI) assays. The results showed a strong correlation between protection against malaria attacks and levels of immunoglobulin G2 (IgG2) and IgG3 against GLURP(94-489) (R0) and IgG3 against GLURP(705-1178) (R2) when corrected for the confounding effect of age-related exposure to malaria. Thus, GLURP may play a role in the induction of protective immunity against P. falciparum malaria.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10768952      PMCID： PMC97467          DOI： 10.1128/IAI.68.5.2617-2620.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  22 in total

1.  Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria.

Authors:  D Dodoo; M Theisen; J A Kurtzhals; B D Akanmori; K A Koram; S Jepsen; F K Nkrumah; T G Theander; L Hviid
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

2.  Expression of the high responder/non-responder human Fc gamma RII. Analysis by PCR and transfection into FcR-COS cells.

Authors:  B J Tate; E Witort; I F McKenzie; P M Hogarth
Journal:  Immunol Cell Biol       Date:  1992-04       Impact factor: 5.126

3.  Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity.

Authors:  H Bouharoun-Tayoun; P Druilhe
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

4.  Primary structure and localization of a conserved immunogenic Plasmodium falciparum glutamate rich protein (GLURP) expressed in both the preerythrocytic and erythrocytic stages of the vertebrate life cycle.

Authors:  M B Borre; M Dziegiel; B Høgh; E Petersen; K Rieneck; E Riley; J F Meis; M Aikawa; K Nakamura; M Harada
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

5.  Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia.

Authors:  B Hogh; E Petersen; M Dziegiel; K David; A Hanson; M Borre; A Holm; J Vuust; S Jepsen
Journal:  Am J Trop Med Hyg       Date:  1992-03       Impact factor: 2.345

6.  Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria.

Authors:  A Sabchareon; T Burnouf; D Ouattara; P Attanath; H Bouharoun-Tayoun; P Chantavanich; C Foucault; T Chongsuphajaisiddhi; P Druilhe
Journal:  Am J Trop Med Hyg       Date:  1991-09       Impact factor: 2.345

7.  Criteria for diagnosing clinical malaria among a semi-immune population exposed to intense and perennial transmission.

Authors:  J F Trape; P Peelman; B Morault-Peelman
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

8.  Possible role of specific immunoglobulin M antibodies to Plasmodium falciparum antigens in immunoprotection of humans living in a hyperendemic area, Burkina Faso.

Authors:  C Boudin; B Chumpitazi; M Dziegiel; F Peyron; S Picot; B Hogh; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1993-03       Impact factor: 5.948

9.  Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children.

Authors:  M Dziegiel; P Rowe; S Bennett; S J Allen; O Olerup; A Gottschau; M Borre; E M Riley
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding.

Authors:  P A Warmerdam; J G van de Winkel; A Vlug; N A Westerdaal; P J Capel
Journal:  J Immunol       Date:  1991-08-15       Impact factor: 5.422
View more
  67 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Plasmodium falciparum merozoite surface protein 1 (MSP-1)-MSP-3 chimeric protein: immunogenicity determined with human-compatible adjuvants and induction of protective immune response.

Authors:  Suman Mazumdar; Paushali Mukherjee; Syed Shams Yazdani; S K Jain; Asif Mohmmed; Virander Singh Chauhan
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

3.  Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.

Authors:  Jean Claude Dejon-Agobe; Ulysse Ateba-Ngoa; Albert Lalremruata; Andreas Homoet; Julie Engelhorn; Odilon Paterne Nouatin; Jean Ronald Edoa; José F Fernandes; Meral Esen; Yoanne Darelle Mouwenda; Eunice M Betouke Ongwe; Marguerite Massinga-Loembe; Stephen L Hoffman; B Kim Lee Sim; Michael Theisen; Peter G Kremsner; Ayôla A Adegnika; Bertrand Lell; Benjamin Mordmüller
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

4.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

5.  Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.

Authors:  Soe Soe; Michael Theisen; Christian Roussilhon; Khin-Saw Aye; Pierre Druilhe
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Development of fluorescent Plasmodium falciparum for in vitro growth inhibition assays.

Authors:  Danny W Wilson; Brendan S Crabb; James G Beeson
Journal:  Malar J       Date:  2010-06-03       Impact factor: 2.979

7.  Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections.

Authors:  Cathrine Holm Olesen; Karima Brahimi; Brian Vandahl; Susana Lousada-Dietrich; Prajakta S Jogdand; Lasse S Vestergaard; Daniel Dodoo; Peter Højrup; Michael Christiansen; Severin Olesen Larsen; Subhash Singh; Michael Theisen
Journal:  Malar J       Date:  2010-10-26       Impact factor: 2.979

8.  Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.

Authors:  Sodiomon B Sirima; Alfred B Tiono; Alphonse Ouédraogo; Amidou Diarra; André Lin Ouédraogo; Jean Baptiste Yaro; Espérance Ouédraogo; Adama Gansané; Edith C Bougouma; Amadou T Konaté; Youssouf Kaboré; Abdoulaye Traoré; Roma Chilengi; Chilengi Roma; Issiaka Soulama; Adrian J F Luty; Pierre Druilhe; Simon Cousens; Issa Nébié
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

9.  The quantity and quality of African children's IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.

Authors:  David Courtin; Mayke Oesterholt; Harm Huismans; Kwadwo Kusi; Jacqueline Milet; Cyril Badaut; Oumar Gaye; Will Roeffen; Edmond J Remarque; Robert Sauerwein; André Garcia; Adrian J F Luty
Journal:  PLoS One       Date:  2009-10-27       Impact factor: 3.240

10.  Design and pre-clinical profiling of a Plasmodium falciparum MSP-3 derived component for a multi-valent virosomal malaria vaccine.

Authors:  Marco Tamborrini; Markus S Mueller; Sabine A Stoffel; Nicole Westerfeld; Denise Vogel; Francesca Boato; Rinaldo Zurbriggen; John A Robinson; Gerd Pluschke
Journal:  Malar J       Date:  2009-12-30       Impact factor: 2.979
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.